Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it
will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day,
hosted by the Alliance for Regenerative Medicine, to be held in New York City
on March 21, 2019. Unique to the medical and biotech communities, the investor
conference focuses on fast-paced, concise presentations from more than 35
companies, consolidated to a one-day conference while allowing opportunities
for one-on-one partnering with venture and strategic investors. Genprex’s
presentation is scheduled for Thursday, March 21, at 2:30-2:45 p.m. EDT in the
Main Bar Room of the Metropolitan Club, One East 60th Street, New York, NY
10022. “I’m looking forward to attending Cell & Gene Therapy Investor Day
for the first time, with the opportunity to share information about Genprex’s
mission and our gene therapy technologies,” Genprex President and COO Julien
Pham, MD, MPH said in the news release. “With a wide array of companies and
industry leaders all presenting in a single day, this conference enables us and
the investment community to take the pulse of where the industry is heading. It
is an incredible honor to be a part of this event.”
To view the full press release, visit http://ibn.fm/BhatA
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and taken up by
tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment